Key result
Ticagrelor with hemoadsorption is linked to ~70% lower BARC-4 bleeding vs clopidogrel in urgent CABG.
Why the study?
ACS patients on DAPT requiring urgent CABG are at high risk for severe bleeding complications, and the impact of P2Y12 inhibitor choice with intraoperative hemoadsorption on perioperative bleeding is unclear.
Does ticagrelor + aspirin + intraoperative hemoadsorption reduce CABG-specific bleeding in ACS patients requiring urgent CABG compared to clopidogrel + aspirin?
Cohort (n=956)
Yes
Does ticagrelor + aspirin + intraoperative hemoadsorption reduce CABG-specific bleeding in ACS patients requiring urgent CABG compared to clopidogrel + aspirin?
In ACS patients requiring urgent CABG, a strategy of ticagrelor with intraoperative hemoadsorption significantly reduced severe perioperative bleeding compared to clopidogrel.
Answers are grounded in this paper and cite their sources.
May support hemoadsorption to reduce bleeding on ticagrelor before urgent CABG; leaves open randomized confirmation before practice change.
All articles of this category (opens in new window) Background: ACS patients on DAPT requiring urgent CABG are at high risk for bleeding complications. Published reports show severe CABG bleeding in up to 1/3 of these cases. Intraoperative hemoadsorption (HA) can remove ticagrelor from circulation and potentially mitigate this high perioperative bleeding risk. Methods: We compared CABG bleeding rates in two cohorts according to two different strategies: Group 1: Ticagrelor + Aspirin + intraoperative HA from the International Safe and Timely Antithrombotic Removal (STAR) registry (ClinicalTrials.gov identifier: NCT05077124). Group 2 was derived from the North Rhine-Westphalia surgical myocardial infarction registry, consisting of Clopidogrel + Aspirin patients. The primary outcome was the CABG-specific bleeding endpoint, summarized by Bleeding Academic Research Consortium (BARC)-4 rates. Results: Prior to matching, Group 1 ( n = 136) compared to Group 2 ( n = 820) showed a significant difference in age ( p < 0.001) and chronic renal disease ( p = 0.04). Crude BARC-4 rates were significantly lower in Group 1 compared with Group 2 (8.9% vs. 32.6%, p < 0.0001), as was the rate of patients requiring ≥ 5 units of red blood cells within 24 hours ( p < 0.0001) and 24-hr chest tube drainage ( p < 0.0001). The 1:3 propensity score adjusted outcomes (113 vs. 339 patients) showed similar results of BARC-4 bleeding events (9.7% vs. 32.3%, p < 0.0001). Overall, BARC-4 bleeding events were more likely in group 2 (OR: 4.7, 95% CI: 2.36–9.49). Conclusion: The current analysis of two different DAPT strategies in ACS used in real-world practice showed significant reductions in severe bleeding complications after CABG with ticagrelor and intraoperative HA. Current ACS guidelines already recommend ticagrelor over clopidogrel in ACS due to better protection from ischemic events. The present analysis, however, adds the advantage of significantly reduced BARC Type 4 bleeding with intraoperative HA among the 5 to 10% of ACS patients who need urgent CABG. Publication History Article published online: 17 February 2026 © 2026. Thieme. All rights reserved. Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
No takes yet. Share an insight, caveat, or question.
Thielmann et al. (2026) conducted a cohort in Acute Coronary Syndrome (ACS) requiring urgent CABG (n=956). Ticagrelor + Aspirin + intraoperative hemoadsorption vs. Clopidogrel + Aspirin was evaluated on CABG-specific bleeding (BARC-4 rates) (OR 4.7, 95% CI 2.36-9.49, p=<0.0001). In ACS patients requiring urgent CABG, ticagrelor with intraoperative hemoadsorption reduced BARC-4 bleeding compared to clopidogrel.
Synapse has enriched 10 related papers. Consider them for comparative context: